ERBB2 and breast carcinoma: To further explore the potential application of combination of NF‐κB inhibitors with copper chelators, we employed human breast cancer organoids, and observed that the combination therapy dramatically promoted organoid destruction and apoptosis both in HER2‐positive and triple negative breast cancer derived organoids (Figure6A,B; Figure S12A–D, Supporting Information).